Clinical Trial Update: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the 13-valent pneumococcal conjugate vaccine in children with sickle cell disease has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Sickle Cell Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2014-04-21